Heparin-associated thrombocytopenia treatment with low molecular weight heparin

Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

Saved in:

Bibliographic Details
Published in:	Thrombosis and haemostasis Vol. 55; no. 1; p. 37
Main Authors:	Vitoux, J F, Mathieu, J F, Roncato, M, Fiessinger, J N, Aiach, M
Format:	Journal Article
Language:	English
Published:	Germany 28-02-1986
Subjects:	Aged Blood Platelets - immunology Female Heparin - adverse effects Heparin - therapeutic use Humans Immunoglobulin G - metabolism Male Middle Aged Platelet Count Thrombocytopenia - chemically induced Thrombocytopenia - complications Thrombocytopenia - drug therapy Thrombosis - complications Thrombosis - drug therapy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.
ISSN:	0340-6245
DOI:	10.1055/s-0038-1661442